From One Cancer to Two: [¹⁸F]FES PET/CT Redirected Diagnosis and Therapy in a Metastatic Breast Cancer Patient.
TL;DR
FES PET/CT proved crucial in differentiating synchronous primary malignancies from metastatic spread and guiding targeted therapy with dabrafenib-trametinib.
OpenAlex 토픽 ·
Multiple and Secondary Primary Cancers
Lung Cancer Treatments and Mutations
Cancer Diagnosis and Treatment
FES PET/CT proved crucial in differentiating synchronous primary malignancies from metastatic spread and guiding targeted therapy with dabrafenib-trametinib.
APA
Anne-Claire Dupont, Mathieu Farges, et al. (2026). From One Cancer to Two: [¹⁸F]FES PET/CT Redirected Diagnosis and Therapy in a Metastatic Breast Cancer Patient.. Clinical nuclear medicine, 51(5), 419-420. https://doi.org/10.1097/RLU.0000000000006386
MLA
Anne-Claire Dupont, et al.. "From One Cancer to Two: [¹⁸F]FES PET/CT Redirected Diagnosis and Therapy in a Metastatic Breast Cancer Patient.." Clinical nuclear medicine, vol. 51, no. 5, 2026, pp. 419-420.
PMID
41730259
Abstract
A 59-year-old woman with an ulcerated right breast lesion was diagnosed with ER-positive invasive ductal carcinoma. Staging [¹⁸F]FDG PET/CT revealed intense uptake in the breast, axillary nodes, a large hypermetabolic pulmonary mass, mediastinal lymphadenopathies, and bone lesions. Because of this metabolic pattern, [¹⁸F]FES PET/CT was performed, demonstrating [¹⁸F]FES-avid bone metastases but no uptake in the lung mass. Biopsy confirmed a BRAF V600E-mutated lung adenocarcinoma. [¹⁸F]FES PET/CT proved crucial in differentiating synchronous primary malignancies from metastatic spread and guiding targeted therapy with dabrafenib-trametinib.
MeSH Terms
Humans; Middle Aged; Female; Breast Neoplasms; Positron Emission Tomography Computed Tomography; Neoplasm Metastasis; Lung Neoplasms